TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10 According to Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $121.10, significantly above its current trading price of $79.79. The company reported mixed quarterly results, beating revenue estimates but missing on earnings per share. Insider activity shows Director David Weill increased his stake, and institutional investors hold a substantial majority of the company's stock.
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
The article summarizes recent analyst ratings for three healthcare companies: TransMedics Group (TMDX), Regeneron (REGN), and Tarsus Pharmaceuticals (TARS). TransMedics Group received a "Moderate Buy" consensus with a $120.00 price target from TD Cowen and a "Buy" from William Blair. Regeneron was rated "Moderate Buy" with a $850.38 consensus price target, despite a "Hold" rating from Leerink Partners and RBC Capital. Tarsus Pharmaceuticals garnered a "Strong Buy" consensus with an average price target of $100.11, receiving "Buy" ratings from Oppenheimer and Goldman Sachs.
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score o
TransMedics Group Inc (TMDX) shares recently fell 5.8%, closing at $78.64, significantly below its GF Value™ of $159.37, suggesting it is undervalued with a 50.7% margin of safety. Despite an above-average GF Score™ of 74/100 and strong growth potential (9/10), the company exhibits weak profitability (3/10) and has seen net insider selling of $3.8 million over the past year. This mixed sentiment from insiders and gurus, coupled with the "possible value trap" label, advises caution and thorough due diligence for potential investors.
CapEx per share of TransMedics Group, Inc. – HAN:8T8
The article provides financial information for TransMedics Group, Inc. (HAN:8T8) focusing on its CapEx per share. It notes that the market is closed with no trades, indicating a static financial snapshot. The content is presented without specific numerical data for the CapEx per share.
TransMedics Group (TMDX), Why Is It Back In The Spotlight?
TransMedics Group (TMDX) is gaining investor attention after a director purchased shares. Despite a 21% rebound in 90 days, the stock is still down 32% year-to-date, though it shows a 64% return over three years. Analysts consider the stock 14% undervalued, with a fair value of $97.30, citing potential for growth through international expansion, while acknowledging risks like regulatory scrutiny.
TMDX5812024 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the TMDX5812024 bond issued by TransMedics Group, Inc. It outlines key facts such as the issuer, maturity date, face value, and coupon rate. The bond has a 1.5% fixed rate, semi-annual coupon payments, and a maturity date of June 1, 2028.
TransMedics CFO Fernando N. Araujo Files Initial SEC Ownership Disclosure Reporting No Shares
Fernando N. Araujo, the newly appointed CFO and Treasurer of TransMedics Group, Inc., filed his initial SEC ownership disclosure (Form 3) on September 29, 2026. This filing indicated that he beneficially owned no securities of TransMedics as of the triggering event date, September 21, 2026. The disclosure fulfills the requirements of Section 16(a) of the Securities Exchange Act, which mandates such reports for company officers upon assuming their roles.
[Form 3] TransMedics Group, Inc. Initial Statement of Beneficial Ownership
This article details the initial statement of beneficial ownership (Form 3) filed by Fernando N. Araujo for TransMedics Group, Inc. (TMDX). The filing indicates that Araujo, identified as the Chief Financial Officer and Treasurer, does not beneficially own any securities as of the event date of September 21, 2026. The document also includes information about the company's recent news and SEC filings, such as Araujo's appointment as CFO.
Net margin % of TransMedics Group, Inc. – HAN:8T8
This page displays the net margin percentage for TransMedics Group, Inc. (HAN:8T8) on the TradingView platform. It provides financial overview, market data, and links to various features and resources offered by TradingView, including charts, screeners, news, and community sections.
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
TransMedics Director David Weill recently purchased 1,336 shares of the company's stock, valued at $109,000. This insider transaction is seen as a vote of confidence in the company, which is a commercial-stage medical technology enterprise specializing in organ transplant therapy. Despite the stock's one-year return of -30% leading up to the purchase, the author recommends TransMedics as a buy, citing its strong growth potential and innovative Organ Care System.
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
TransMedics Group Director David Weill recently purchased 1,336 shares of the company's common stock for approximately $109,000, increasing his direct holdings to 16,392 shares. While this insider buy signifies confidence in the medical technology company, the article suggests it should be considered a tiebreaker rather than a primary reason to invest, given the amount is relatively small for a multi-billion dollar company. TransMedics, which specializes in organ transplant technology, is projected to have 22-25% sales growth in 2026 and is seen as a strong buy by the author due to its innovative Organ Care System and expansion plans.
Operating expenses (excl. COGS) of TransMedics Group, Inc. – HAN:8T8
This article focuses on the operating expenses (excluding COGS) of TransMedics Group, Inc., traded under the ticker HAN:8T8 on the Hannover Stock Exchange. The content provided is primarily a placeholder for financial data that would typically be displayed on a financial information platform like TradingView. It highlights the availability of such data for investors and analysts.
TransMedics offers a unique organ transplant tech platform, with growth driven by new kidney product and global expansion.
TransMedics is a leading organ transplant technology company known for its multi-organ perfusion platform and integrated logistics. Despite recent stock fluctuations, its long-term potential is driven by a new kidney Organ Care System product expected by 2027 and global expansion, with a revenue target exceeding $2 billion by 2032. However, the company is also facing an investigation into potential leadership breaches.
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal actions, such as seeking corporate governance reforms or the return of funds to the company. The firm emphasizes that shareholder involvement can enhance transparency, accountability, and overall shareholder value.
Investors Purchase Large Volume of TransMedics Group Put Options (NASDAQ:TMDX)
Traders recently acquired a significantly high volume of TransMedics Group (NASDAQ:TMDX) put options, suggesting increased hedging or bearish sentiment. This comes as a director increased his stake in the company and institutional investors hold a substantial portion of the shares. Analysts currently have a "Hold" rating on the stock, with a consensus price target of $121.10.
TransMedics Group (NASDAQ:TMDX) Trading Up 4.5% on Insider Buying Activity
TransMedics Group (NASDAQ:TMDX) saw its share price rise 4.5% after Director David Weill purchased 1,336 shares, increasing his stake by almost 9%. The company's latest quarterly revenue exceeded estimates, but adjusted earnings per share missed consensus forecasts. Analysts currently hold a "Hold" rating on the stock with an average price target of $124.18.
Insider Buying: TransMedics Group (NASDAQ:TMDX) Director Buys 1,336 Shares of Stock
TransMedics Group Director David Weill recently purchased 1,336 shares of TMDX stock for approximately $109,058, increasing his direct ownership by 8.87%. The company's shares rose 4.5% following the transaction, despite missing EPS estimates but exceeding revenue expectations. Institutional investors hold a significant portion of the stock, and analyst ratings are mixed, resulting in an overall "Hold" rating with a consensus price target of $124.18.
TransMedics Group Jumps 6.5% Amid Sector-Wide Rally
TransMedics Group (TMDX) saw a 6.5% increase in its stock price on Monday, closing at $87.53, as medical device stocks experienced a broad sector-wide rally. The surge was attributed to overall market strength rather than company-specific news, with other sector peers like ASST and AXGN also posting significant gains. Investors are advised to monitor whether this sector rally is sustainable or a short-term momentum play.
TransMedics names Fernando Araujo as CFO, reaffirms 2026 outlook
TransMedics Group Inc. has appointed Fernando Araujo as its new Chief Financial Officer, effective September 21, leveraging his two decades of public company finance experience. The company also reaffirmed its full-year 2026 revenue guidance, projecting $737 million to $757 million, representing 22% to 25% year-over-year growth, excluding contributions from a recent investment. Araujo succeeds Gerardo Hernandez, who will transition to a Commercial Strategic Advisor role for Latin America.
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
TransMedics Group, Inc. (Nasdaq: TMDX) has appointed Fernando Araujo as its new Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings over 20 years of finance leadership experience from GE HealthCare, General Electric, and 3M. Concurrently, TransMedics reaffirmed its full-year 2026 revenue guidance of $737 million to $757 million, representing a 22% to 25% year-over-year growth, excluding contributions from its investment in PAD Aviation Service GmbH.
(TMDX) TransMedics Expects Full Year 2026 Revenue Range $737M - $757M, vs. FactSet Est of $743.1M
TransMedics Group, Inc. (TMDX) anticipates its full-year 2026 revenue to fall within the range of $737 million to $757 million. This projection is compared against FactSet's estimated revenue of $743.1 million. The company reiterated this revenue guidance on September 10, 2026.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Hold" by Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus "Hold" rating from brokerages, with six analysts recommending "Buy", six "Hold", and one "Sell." The average 12-month price target is $124.18, significantly higher than its recent trading price of $86.40, following mixed quarterly results where revenue exceeded estimates but EPS missed. The stock is currently down 2.1% and trading below its 52-week high, with recent analyst price target adjustments reflecting a cautious outlook despite some buy ratings.
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
TransMedics Group, Inc. has announced the appointment of Fernando Araujo as its new Chief Financial Officer, effective September 21, 2026. Araujo brings over 20 years of public-company finance leadership experience from GE HealthCare, General Electric, and 3M. Concurrently, the company is reiterating its full-year 2026 revenue guidance of $737 million to $757 million, representing 22% to 25% year-over-year growth.
TransMedics Group's (TMDX) "Buy" Rating Reiterated at TD Cowen
TD Cowen reiterated its "Buy" rating for TransMedics Group (TMDX) with a $120 price target, representing a 37.89% upside. While analyst sentiment is mixed, with a consensus "Hold" rating and an average target price of $124.18, the company's shares recently fell by 3.3%. TransMedics reported a 20.7% year-over-year revenue increase to $189.95 million, though its EPS of $0.44 missed the consensus estimate of $0.50.
Jupiter Topco LLC Makes New Investment in TransMedics Group, Inc. $TMDX
Jupiter Topco LLC recently acquired a new stake of 15,263 shares, valued at approximately $1.014 million, in TransMedics Group, Inc. during the second quarter. Institutional investors now own 99.67% of the company's stock. Despite mixed analyst ratings, with an average price target of $124.18, TransMedics reported strong quarterly revenue growth of 20.7% year-over-year, though earnings per share missed consensus estimates.
TransMedics Group, Inc. $TMDX Position Increased by Wellington Management Group LLP
Wellington Management Group LLP increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 6.1% in the second quarter, now owning 515,973 shares valued at over $34 million. This article details institutional ownership changes, price performance, earnings results, analyst ratings, and insider trading activity for TransMedics Group, highlighting the company's financial metrics and market sentiment.
TransMedics Group, Inc. $TMDX Position Increased by FirstWave Capital Management LLC
FirstWave Capital Management LLC significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 53.9% in the second quarter, now holding 191,240 shares valued at approximately $12.7 million. Despite positive revenue growth, the company missed EPS estimates, and analyst ratings are mixed, resulting in an average "Hold" rating. The stock's current trading price is well below its 12-month high.
19,289 Shares in TransMedics Group, Inc. $TMDX Bought by Corient Private Wealth LP
Corient Private Wealth LP recently acquired 19,289 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $1.28 million, increasing institutional ownership to 99.67%. Analyst opinions on TMDX are divided, with a "Hold" consensus rating and an average price target of $124.18. Despite reporting strong quarterly revenue growth of 20.7% to $189.95 million, the company's earnings per share of $0.44 missed analyst estimates.
Legal & General Group Plc Invests $5.29 Million in TransMedics Group, Inc. $TMDX
Legal & General Group Plc has invested approximately $5.29 million in TransMedics Group, Inc. by acquiring 79,582 shares, representing 0.23% of the company. Institutional investors collectively own 99.67% of TransMedics, which has a mixed analyst sentiment with a consensus "Hold" rating and a target price of $124.18. Despite exceeding revenue estimates with $189.95 million, TransMedics missed earnings per share expectations, reporting $0.44 against an anticipated $0.50.
TransMedics Group, Inc. $TMDX Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS Asset Management significantly reduced its stake in TransMedics Group (TMDX) by 57.6% in the second quarter, selling over 541,000 shares but still holding 398,250 shares valued at approximately $26.5 million. While TransMedics reported strong quarterly revenue growth of 20.7% to $189.95 million, its earnings per share of $0.44 missed analyst estimates of $0.50. Analyst sentiment for TMDX is currently mixed, with a consensus "Hold" rating and an average price target of $124.18 against its current trading price of $86.98.
Braidwell LP Has $40.50 Million Position in TransMedics Group, Inc. $TMDX
Braidwell LP significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 85.1% in the second quarter, bringing its total position to 609,715 shares valued at approximately $40.5 million. Despite institutional ownership of nearly 100%, analyst sentiment for TMDX is mixed, with a consensus "Hold" rating and an average price target of $124.18. TransMedics Group reported strong revenue growth but missed EPS estimates, and its stock currently trades well below its 52-week high.
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm, a global investor rights law firm, has announced that it is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders of TransMedics Group to visit its website for more information or to contact Phillip Kim. Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, having recovered billions for investors.
TransMedics Group, Inc. $TMDX Shares Sold by Beaconlight Capital LLC
Beaconlight Capital LLC reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 63.7% in Q2 2026, selling 27,072 shares and retaining 15,406 shares valued at $1.02 million. Institutional investors and hedge funds collectively own 99.67% of TMDX. Analysts have a mixed sentiment, with a consensus "Hold" rating and an average price target of $124.18, following varied rating changes and a recent earnings report where revenue exceeded estimates but EPS missed.
Algert Global LLC Purchases 31,710 Shares of TransMedics Group, Inc. $TMDX
Algert Global LLC significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, purchasing 31,710 additional shares to own a total of 57,154 shares valued at $3.8 million. Institutional investors now collectively hold 99.67% of the company. Despite a 20.7% year-over-year revenue increase to $189.95 million, TransMedics missed earnings estimates at $0.44 per share against a $0.50 consensus.
TransMedics Group, Inc. (TMDX) Stock Analysis: Exploring Growth Potential with a Robust 36.29% ROE
TransMedics Group, Inc. (TMDX) is a medical technology company specializing in organ transplant therapy, demonstrating strong financial performance with a 36.29% return on equity and 20.70% revenue growth. The stock trades near its average target price, with analysts largely issuing buy recommendations, indicating confidence in its growth potential despite market volatility. The company's focus on reinvestment rather than dividends positions it as an appealing option for growth-oriented investors.
Biondo Investment Advisors LLC Purchases New Position in TransMedics Group, Inc. $TMDX
Biondo Investment Advisors LLC has acquired a new stake of 44,155 shares, valued at approximately $2,933,000, in TransMedics Group, Inc. during the second quarter. Other institutional investors also bought new stakes in the company, bringing the total institutional ownership to 99.67%. The article also discusses recent analyst ratings, the company's financial performance, and a recent insider stock sale.
EP Wealth Advisors LLC Purchases Shares of 15,401 TransMedics Group, Inc. $TMDX
EP Wealth Advisors LLC recently acquired a new stake of 15,401 shares in TransMedics Group, Inc., valued at approximately $1.02 million, bringing institutional ownership of the company's stock to 99.67%. Despite mixed analyst ratings and a consensus "Hold" rating, TransMedics reported strong quarterly revenue growth of 20.7%, though earnings per share missed consensus estimates. The stock currently trades significantly below its 12-month high, reflecting a volatile market performance.
30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC
Emerald Investment Advisers LLC recently acquired 30,456 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $2.02 million, contributing to institutional investors owning 99.67% of the company. Despite reporting strong revenue growth, TransMedics missed earnings per share estimates, and analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $124.18.
Deutsche Bank AG Makes New Investment in TransMedics Group, Inc. $TMDX
Deutsche Bank AG has acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 217,031 shares valued at approximately $14.415 million, representing about 0.63% of the company. Other institutional investors have also adjusted their positions in TMDX, with 99.67% of the stock owned by hedge funds and institutions. The article also notes recent stock performance, earnings results where the company missed EPS estimates but beat revenue expectations, and a recent insider stock sale.
Trillium Asset Management LLC Takes $2.76 Million Position in TransMedics Group, Inc. $TMDX
Trillium Asset Management LLC has acquired a new stake of 41,577 shares, valued at $2.76 million, in TransMedics Group, Inc. during the second quarter. This move comes as other institutional investors have also adjusted their holdings in TMDX, with institutional ownership now at 99.67%. Despite TransMedics Group exceeding revenue estimates, its earnings per share fell short, leading to mixed analyst ratings and a consensus "Hold" rating for the stock.
TransMedics Group Inc (TMDX) Shares Fall 3.3% -- What GF Score o
TransMedics Group Inc (TMDX) saw its shares fall 3.3% to $90.85, a 25.3% year-to-date decline. Despite being significantly undervalued according to the GF Value™ estimate, the stock carries a "Possible Value Trap" label, and insider activity shows net selling. The company has a strong growth rank but weak profitability, with a GF Score™ of 74/100.
Diversify Advisory Services LLC Purchases Shares of 15,872 TransMedics Group, Inc. $TMDX
Diversify Advisory Services LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 15,872 shares valued at approximately $1.18 million. This acquisition is part of broader institutional investment, with various hedge funds also increasing their stakes in the company, bringing total institutional ownership to 99.67%. Despite strong revenue growth, TransMedics missed earnings estimates for the quarter, and analyst sentiment remains mixed with an average "Hold" rating.
Rosen Law Firm investigates TransMedics Group for possible fiduciary breaches affecting shareholders.
The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. This action could impact current shareholders of TransMedics stock (TMDX). Investors are encouraged to seek legal representation and gather more information from the firm's website or by contacting them directly.
Summit Creek Advisors LLC Takes $1.77 Million Position in TransMedics Group, Inc. $TMDX
Summit Creek Advisors LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 26,707 shares valued at approximately $1.77 million. This makes Summit Creek Advisors LLC the owner of 0.08% of TransMedics Group, with institutional investors collectively holding 99.67% of the stock. Despite reporting strong quarterly revenue growth of 20.7% to $189.95 million, the company missed earnings per share estimates at $0.44 against a $0.50 consensus.
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group outlined its growth strategy at a recent conference, focusing on kidney transplantation, European expansion through the PAD Aviation acquisition, and broader adoption of its Organ Care System (OCS) for heart and lung transplants. The company aims for a $2 billion revenue base, with specific targets for 2025 revenue guidance of $737 million to $757 million and an adjusted operating margin near 30% by 2028 or after reaching 10,000 transplants. Its strategy leverages a vertically integrated platform to increase organ availability and improve transplant outcomes, estimating a significant opportunity in the kidney market alone.
TransMedics Group, Inc. Investor News: Rosen Law Firm
The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders to visit its website or contact Phillip Kim for more information regarding this investigation. Rosen Law Firm emphasizes its track record of success in investor rights litigation, having recovered billions for investors globally.
TransMedics Group, Inc. Investor News: Rosen Law Firm
The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders to visit its website or contact them for more information regarding this investigation. Rosen Law Firm highlights its track record of success in securities class actions and shareholder derivative litigation.
TransMedics (TMDX) director gifts 18,000 shares
TransMedics Group, Inc. director James R. Tobin reported a bona fide gift transfer of 18,000 shares of common stock from "The Tobin 2024 Family Trust" on August 17, 2026. Following this transaction, the trust holds 0 shares, while Tobin directly holds 6,981 shares and indirectly holds 155,146 shares through another trust. The filing indicates a neutral impact on the stock as it was a gift, not a sale.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) regarding potential breaches of fiduciary duties by its officers and directors. This follows a report by Scorpion Capital alleging fraudulent billing, coercive business practices, and unsafe organ transplantation, leading to a securities class action lawsuit against the company. KSF is inviting long-term shareholders to provide information or discuss their legal rights.
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal rights and options, including corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance transparency, accountability, and overall company management, ultimately improving shareholder value.
